Targeting Ezh2 could overcome docetaxel resistance in prostate cancer cells

BACKGROUND: Docetaxel was used to treat metastatic CRPC patients. However, Doc resistance in prostate cancer (PCa) hinders its clinical application. OBJECTIVE: To understand the underlying mechanisms by which Doc resistance is developed and to find novel therapeutic target to cure Doc resistant PCa...

Descripción completa

Detalles Bibliográficos
Autores principales: Qiu, Xiaofu, Wang, Wei, Li, Bijun, Cheng, Bo, Lin, Kangjian, Bai, Jian, Li, Huanhui, Yang, Guosheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6324167/
https://www.ncbi.nlm.nih.gov/pubmed/30621625
http://dx.doi.org/10.1186/s12885-018-5228-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6324167/
https://www.ncbi.nlm.nih.gov/pubmed/30621625
http://dx.doi.org/10.1186/s12885-018-5228-2

Ejemplares similares